Connect your AI

UroGen Pharma URGN Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers SquibbBMY

$1.1B-43.5%

PfizerPFE

$2.62B+12.0%

Johnson & JohnsonJNJ

$2.51B-39.8%

Merck & Co.MRK

$3.92B+56.7%

ImmunityBio, Inc.IBRX

-$75.36M+12.3%

Tyra Biosciences, Inc.TYRA

-$32.57M-27.9%

Other financials

Income statement

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

Market cap$1.71B+71.7%

Enterprise value$1.8B+80.9%

P/S12.2×+1.3×

Profitability

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is UroGen Pharma's operating cash flow?: UroGen Pharma (URGN) reported operating cash flow of -$45.32M in Q1 2026.
How has UroGen Pharma's operating cash flow changed year-over-year?: UroGen Pharma's operating cash flow decreased by 7.8% year-over-year, from -$42.02M to -$45.32M.
What is the long-term trend for UroGen Pharma's operating cash flow?: Over 4 years (2021 to 2025), UroGen Pharma's operating cash flow has grown at a 17.6% compound annual growth rate (CAGR), from -$84.89M to -$162.44M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.